GlaxoSmithKline Pharmaceuticals Limited (GLAXO.NS)

2,654.85 -45.85 (-1.70%) At close: 03:30PM IST

GlaxoSmithKline Pharmaceuticals Limited

GSK House
Dr. Annie Besant Road
Mumbai 400030
India
91 22 2495 9595
https://india-pharma.gsk.com

Sector(s): Healthcare
Industry: Drug Manufacturers - General
Full Time Employees: 3,211

Key Executives

Name	Title	Pay	Exercised	Year Born
Mr. Bhushan Akshikar	MD & Executive Director	66.89M	N/A	N/A
Mr. Juby Chandy	Whole-Time Director & CFO	68.92M	N/A	1977
Mr. Chinmay Sharma	Executive Vice President of Human Resources	N/A	N/A	N/A
Ms. Aparajita Rajput	Vice President of Technology	N/A	N/A	N/A
Mr. Ajay Avinash Nadkarni	VP of Administration & Real Estate and Company Secretary	N/A	N/A	N/A
Mr. Amit G. Pandey	Executive Vice President of Legal	N/A	N/A	N/A
Ms. Simrat Sohal	Vice President of Ethics & Compliance	N/A	N/A	N/A
Mr. Ransom D'Souza	Executive Vice President of Communications & Government Affairs	N/A	N/A	N/A
Ms. Sukanya Choudhary	Executive Vice-President of Regulatory Affairs	N/A	N/A	N/A
Dr. Rashmi Hegde M.D.	Executive Vice President of Medical	N/A	N/A	N/A

Amounts are as of December 31, 2024 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in INR.

Description

GlaxoSmithKline Pharmaceuticals Limited manufactures, distributes, and trades in pharmaceuticals in India and internationally. The company offers vaccines, such as Infanrix Hexa for vaccination of infants against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis, and disease caused by Haemophilus influenzae type B; Synflorix for active immunization of infants against pneumococcal diseases and acute otitis media; Havrix for active immunization against disease caused by Hepatitis A virus; Menveo to prevent invasive meningococcal disease; Boostrix for immunization against diphtheria, tetanus and pertussis; Fluarix Tetra for the prevention of influenza disease; Varilrix for active immunization against varicella; and Shingrix for prevention of herpes zoster and post-herpetic neuralgia. It also provides specialty medicines comprising NUCALA for severe eosinophilic asthma, eosinophilic granulomatosis with polyangiitis, and hypereosinophilic syndrome; and TRELEGY ELLIPTA for treating chronic obstructive pulmonary disease. In addition, the company offers general medicines, including AUGMENTIN and CEFTUM, which are antibiotics to treat bacterial infections; CALPOL for treatment of mild to moderate pain; ELTROXIN for hypothyroidism; CCM to treat calcium and vitamin D deficiency; NEOSPORIN for treatment and prevention of specific bacterial skin infections; BETNOVATE for skin conditions which require relief of inflammation; T-BACT for bacterial skin infections; and PHYSIOGEL for dry skin and dry skin associated with redness and itch. Further, it develops products for infectious diseases, HIV, oncology, and immunology. The company was formerly known as SmithKline Beecham Pharmaceuticals India Ltd. and changed its name to GlaxoSmithKline Pharmaceuticals Limited in 2001. GlaxoSmithKline Pharmaceuticals Limited was incorporated in 1924 and is headquartered in Mumbai, India.

Corporate Governance

GlaxoSmithKline Pharmaceuticals Limited’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.